However, PD‐1/PD‐L1 interaction has been associated with the suppression of immune responses to myeloma cells,18 and preclinical studies indicated that isatuximab‐induced antibody‐dependent cellular cytotoxicity could be enhanced through the inhibition of PD‐1.19 Here, PDCD1 is linked to plasma cell myeloma.